Immune Inhibitory Molecule PD-1 Homolog (VISTA) Colocalizes with CD11b Myeloid Cells in Melanoma and Is Associated with Poor Outcomes
- 8 August 2023
- journal article
- research article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 144 (1) , 106-115.e4
Abstract
No abstract availableKeywords
Funding Information
- Dermatology Foundation
- Melanoma Research Alliance
This publication has 51 references indexed in Scilit:
- Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responsesProceedings of the National Academy of Sciences, 2015
- Multiplexed Quantitative Analysis of CD3, CD8, and CD20 Predicts Response to Neoadjuvant Chemotherapy in Breast CancerClinical Cancer Research, 2014
- VISTA Is a Novel Broad-Spectrum Negative Checkpoint Regulator for Cancer ImmunotherapyCancer Immunology Research, 2014
- Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunityJournal of Clinical Investigation, 2014
- VISTA Regulates the Development of Protective Antitumor ImmunityCancer Research, 2014
- VISTA Is an Immune Checkpoint Molecule for Human T CellsCancer Research, 2014
- Cutting Edge: A Monoclonal Antibody Specific for the Programmed Death-1 Homolog Prevents Graft-versus-Host Disease in Mouse ModelsThe Journal of Immunology, 2011
- VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responsesJournal of Experimental Medicine, 2011
- X-TileClinical Cancer Research, 2004
- Automated subcellular localization and quantification of protein expression in tissue microarraysNature Medicine, 2002